由于所有树木,看到主要瘤:基于低维数据的癌症类型预测
Julia Gehrmann1, Devina Johanna Soenarto1, Kevin Hidayat1
1Institute for Biomedical Informatics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Frontiers in medicine
|September 11, 2024
概括
常规的临床数据可以有效地预测原发性瘤在未知原发性癌症 (CUP) 综合征中的位置. 这种方法为高维数据提供了一个资源高效的替代方案,以改善诊断和患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 医疗信息学 医疗信息学
- 生物统计学 生物统计学
背景情况:
- 未知原发性癌症 (CUP) 综合征具有可识别的转移,但难以捉摸的原发性瘤的诊断挑战.
- 预测原发瘤 (LOP) 的位置对于有效的CUP患者管理和改善结果至关重要.
- 目前的LOP预测方法通常依赖于高维数据,这带来了翻译和资源挑战.
研究的目的:
- 评估用于预测CUP患者LOP的低维,常规临床数据的疗效.
- 将使用常规临床数据的模型与使用高维数据的模型的性能进行比较.
- 确定可访问的临床信息是否可以作为LOP预测模型的可行输入.
主要方法:
- 利用基于树的模型进行LOP预测.
- 采用从常规医疗护理中获得的低维数据作为输入特征.
- 使用十倍嵌套交叉验证 (NCV) 验证模型性能.
- 评估模型在区分四种和八种癌症类型方面的性能.
主要成果:
- 一个表现最好的模型在四种癌症类型中实现了94%的准确性和0.92的MCC得分.
- 该模型在区分八种癌症类型时获得了85%的准确性和0.81的MCC得分.
- 性能与使用高维数据的方法可比.
- 转移分布模式被确定为重要的预测因素.
结论:
- 低维的常规临床数据足以在CUP中准确预测LOP.
- 这种方法为CUP诊断提供了高维数据的实用和资源高效的替代方案.
- 这些发现表明,转移模式是CUP综合征中LOP预测的关键指标.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K